Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial.

Bookmark this %label%

In this secondary analysis of the EMPEROR-Reduced trial, we sought to evaluate whether the benefits of empagliflozin varied by baseline health status and how empagliflozin impacted patient-reported outcomes in patients […]

» Read more

Effect of Renal Dysfunction on Risk of Sudden Cardiac Death in Patients with Hypertrophic Cardiomyopathy.

Bookmark this %label%

Renal dysfunction is a known risk of sudden cardiac death in patients with ischemic heart disease. However, the association between renal dysfunction and sudden death in hypertrophic cardiomyopathy (HC) patients […]

» Read more

N-terminal pro-brain natriuretic peptide and sudden cardiac death in hypertrophic cardiomyopathy.

Bookmark this %label%

Elevated levels of N-terminal pro-brain natriuretic peptide (NT-proBNP) are associated with heart failure-related death in hypertrophic cardiomyopathy (HCM), but the relationship between NT-proBNP level and sudden cardiac death (SCD) in […]

» Read more

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes.

Bookmark this %label%

The EMPERIAL (Effect of EMPagliflozin on ExeRcise ability and HF symptoms In patients with chronic heArt faiLure) trials evaluated the effects of empagliflozin on exercise ability and patient-reported outcomes in […]

» Read more

Sudden Unexpected Death Due to Myocarditis in Young People, Including Athletes.

Bookmark this %label%

Sudden deaths in young active people and athletes are distinctly uncommon and frequently related to highly visible cardiovascular conditions including hypertrophic cardiomyopathy and congenital coronary anomalies. Myocarditis is also a […]

» Read more

Risk of Hypertrophic Cardiomyopathy with Contemporary Management Strategies Implemented In Non-Referral Regional Community-Based Practices.

Bookmark this %label%

Major advances in diagnosis and treatment have emerged for hypertrophic cardiomyopathy (HCM), largely in major tertiary referral centers dedicated to this disease. Whether these therapeutic benefits are confined to patients […]

» Read more

Impact of Tafamidis on Health-Related Quality of Life in Patients with Transthyretin Amyloid Cardiomyopathy (From the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial).

Bookmark this %label%

In the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT), tafamidis significantly reduced all-cause mortality and cardiovascular-related hospitalizations in patients with transthyretin amyloid cardiomyopathy (ATTR-CM). ATTR-CM is associated with a significant […]

» Read more

Arrhythmias right ventricular cardiomyopathy and sports activity: from molecular pathways in diseased hearts to new insights into the athletic heart mimicry.

Bookmark this %label%

Arrhythmogenic right ventricular cardiomyopathy (ARVC) is an inherited disease associated with a high risk of sudden cardiac death. Among other factors, physical exercise has been clearly identified as a strong […]

» Read more

Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.

Bookmark this %label%

The selective cardiac myosin activator omecamtiv mecarbil has been shown to improve cardiac function in patients with heart failure with a reduced ejection fraction. Its effect on cardiovascular outcomes is […]

» Read more

Cardiovascular genetics: the role of genetic testing in diagnosis and management of patients with hypertrophic cardiomyopathy.

Bookmark this %label%

Genetic testing in hypertrophic cardiomyopathy (HCM) is a valuable tool to manage patients and their families. Genetic testing can help inform diagnosis and differentiate HCM from other disorders that also […]

» Read more

Characteristics and Longer-Term Outcomes of Contemporary Patients <18 Years of Age with Hypertrophic Cardiomyopathy.

Bookmark this %label%

We describe characteristics and outcomes of contemporary pediatric hypertrophic cardiomyopathy (PHC) patients. We studied 398 consecutive pediatric HC patients (<18 years, median 14 years, 65% boys) seen at our center […]

» Read more

Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences.

Bookmark this %label%

The dilated cardiomyopathy (DCM) phenotype is the result of combined genetic and acquired triggers. Until now, clinical decision-making in DCM has mainly been based on ejection fraction (EF) and NYHA […]

» Read more

Relation of Neighborhood Disadvantage to Heart Failure Symptoms and Hospitalizations.

Bookmark this %label%

Residence in socioeconomically deprived neighborhoods may influence patient’s health-related behaviors and overall health. We evaluated the association of neighborhood disadvantage on heart failure (HF) symptom burden and hospitalization rates. We […]

» Read more

Association between right ventricular strain and outcomes in patients with dilated cardiomyopathy.

Bookmark this %label%

To explore the association between three-dimensional (3D) cardiac magnetic resonance (CMR) feature tracking (FT) right ventricular peak global longitudinal strain (RVpGLS) and major adverse cardiovascular events (MACEs) in patients with […]

» Read more

Considering complexity in the genetic evaluation of dilated cardiomyopathy.

Bookmark this %label%

Dilated cardiomyopathy (DCM) is a cardiovascular disease of genetic aetiology that causes substantial morbidity and mortality, and presents considerable opportunity for disease mitigation and prevention in those at risk. Foundational […]

» Read more

Two-year outcome after implantation of a full magnetically levitated left ventricular assist device: results from the ELEVATE Registry.

Bookmark this %label%

The ELEVATE Registry was designed to study long-term outcomes with the Heartmate 3 (HM3), a fully magnetically levitated centrifugal ventricular assist device, in a real-world population following CE-mark approval.A total […]

» Read more

Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.

Bookmark this %label%

Patients with heart failure and preserved ejection fraction (HFpEF) are at high risk of mortality, hospitalizations, and reduced functional capacity and quality of life.To assess the efficacy of the oral […]

» Read more

Trends and Impact of the Use of Mechanical Circulatory Support for Cardiogenic Shock Secondary to Takotsubo Cardiomyopathy.

Bookmark this %label%

Data on the trend and impact of mechanical circulatory support (MCS) in patients with Takotsubo cardiomyopathy (TC) are scarce. We evaluated the incidence and outcomes of cardiogenic shock (CS) in […]

» Read more

Diagnostic Usefulness of Histological Examination of the Left Ventricular “Core” Excised to Insert a Left Ventricular Assist Device in Patients with Severe Heart Failure.

Bookmark this %label%

The left ventricular assist device (LVAD) has proven to be beneficial for patients with severe heart failure poorly responsive to anti heart failure medicine. To examine both grossly and histologically […]

» Read more

Discovery of TITIN Gene Truncating Variant Mutations and 5-year Outcomes in Patients with Non-Ischemic Dilated Cardiomyopathy.

Bookmark this %label%

Genetic factors play an important role in non-ischemic dilated cardiomyopathy (NIDC). However, prime opportunities remain for genetic discovery and prognostic understanding. TITIN gene truncating variant mutations (TTNtv) are of interest […]

» Read more

Predictors and Mechanisms of Atrial Fibrillation in Patients with Hypertrophic Cardiomyopathy.

Bookmark this %label%

Atrial fibrillation (AF) in hypertrophic cardiomyopathy (HC) is associated with significant symptomatic deterioration, heart failure and thromboembolic disease. There is a need for better mechanistic insight and improved identification of […]

» Read more

Comparison of Mortality and Readmission in Non-Ischemic Versus Ischemic Cardiomyopathy After Implantable Cardioverter-Defibrillator Implantation.

Bookmark this %label%

Data is lacking on the contemporary risk of death and readmission following implantable cardioverter-defibrillator (ICD) implantation in patients with non-ischemic cardiomyopathies (NICM) compared with ischemic cardiomyopathies (ICM) in a large […]

» Read more

Familial LEOPARD Syndrome With Hypertrophic Cardiomyopathy.

Bookmark this %label%

Multiple lentigines syndrome is an autosomal dominant inherited condition with variable expressivity that is also known as LEOPARD syndrome. LEOPARD stands for lentigines, electrocardiographic conduction defects, ocular hypertelorism, pulmonary valve […]

» Read more

Improvement of ejection fraction and mortality in ischaemic heart failure.

Bookmark this %label%

The frequency and predictors of improvement in left ventricular ejection fraction (LVEF) in ischaemic cardiomyopathy and its association with mortality is poorly understood. We sought to assess the predictors of […]

» Read more

Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry.

Bookmark this %label%

We sought to describe the clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy (PPCM) globally.In 2011, >100 national and affiliated member cardiac societies of the European Society […]

» Read more

Natural History and Disease Progression of Early Cardiac Amyloidosis Evaluated by Echocardiography.

Bookmark this %label%

Since the diagnosis of cardiac amyloidosis (CA) is often delayed, echocardiographic findings are frequently indicative of advanced cardiomyopathy. We aimed to describe early echocardiographic features in patients subsequently diagnosed with […]

» Read more

Ventricular Septal Myectomy for the Treatment of Left Ventricular Outflow Tract Obstruction Due to Fabry Disease.

Bookmark this %label%

Fabry cardiomyopathy can cause symptomatic left ventricular outflow tract obstruction. We review a case of Fabry cardiomyopathy mimicking hypertrophic cardiomyopathy on echocardiography with severe left ventricular outflow tract obstruction treated […]

» Read more
1 2 3 5